The European Commission (EC) has granted marketing authorization for Ebvallo (tabelecleucel)vas a monotherapy for treatment of adult and pediatric patients two years of age and older with relapsed or refractory Epstein‑Barr virus positive post‑transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.
The EC nod was granted to US biotech Atara Biotherapies (Nasdaq: ATRA), whose shares edged up 3.4% to $3.64 in pre-market trading.
The approval follows a positive opinion in October by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) and applies to all 27 European Union member states plus Iceland, Norway and Liechtenstein. The CHMP positive opinion is based on results from the pivotal Phase III ALLELE study, in which Ebvallo demonstrated a favorable risk-benefit profile.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze